WebPer-Share Earnings, Actuals & Estimates Cytokinetics Inc. Quarterly Annual Actual Analyst Range Consensus 0.50 0.00 -0.50 -1.00 -1.50 CYTK will report Q1 earnings on … WebMar 7, 2024 · Cytokinetics (CYTK) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St View Valuation Cytokinetics Future Growth Future criteria checks 0/6 Cytokinetics, Incorporated's earnings is forecasted to decline at 23.5% and its revenue is expected to decline at 46.6%.
Broker Revenue Forecasts For Cytokinetics, Incorporated (NASDAQ:CYTK ...
WebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get... WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ... crystalaire enumclaw
Analysts Have Conflicting Sentiments on These …
WebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19. WebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, … Web1 day ago · Similarly, MAC has 32.06% upside from the recent share price of $9.92 if the average analyst target price of $13.10/share is reached, and analysts on average are expecting HR to reach a target ... duty free shop toronto pearson airport